Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interim PET-CT Guided Therapy in Advanced Hodgkin's Lymphoma
NCT01304849Phase 2Completed
- Sponsor
- Cancer Institute (WIA)
- Start
- Jan 2011
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bleomycin, etoposide, pegylated liposomal doxorubicin, cyclophosphamide, vincristine sulfate liposome injection in Hodgkin lymphoma (HL), sponsored by Cancer Institute (WIA). Started Jan 2011; status: completed.
02
Drugs
bleomycinetoposidepegylated liposomal doxorubicincyclophosphamidevincristine sulfate liposome injection
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01304849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01304849.